Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Bortezomib
- Accession Number
- DB00188 (APRD00828, DB07475)
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
Bortezomib (originally PS-341 and marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. The boron atom within bortezomib catalytically binds the active site of the 26S proteasome with high affinity and specificity, thereby resulting in cell cycle arrest and apoptosis. In normal cells, the proteasome is involved in degradation of ubiquitylated proteins that have been tagged for destruction because they are damaged or unneeded by the cell. However, in cancerous cells, proteasome activity degrades pro-apoptotic proteins such as p53 that would normally result in programmed cell death of the dysfunctional cells. Proteasome inhibitors such as bortezomib interrupt this process, resulting in destruction of cancerous cells.
Bortezomib is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.
- Structure
Structure for DB00188 (Bortezomib)
- Synonyms
- [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
- N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
- N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
- External IDs
- LDP 341 / LDP-341 / LDP341 / BXCL 101 / BXCL-101 / BXCL101 / LDP-341 / PS 341 / PS-341 / PS341
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Act Bortezomib Powder, for solution 3.5 mg Intravenous; Subcutaneous Actavis Pharma Company 2015-11-17 Not applicable Canada 
Bortezomib Powder, for solution 3.5 mg Intravenous; Subcutaneous Apotex Corporation Not applicable Not applicable Canada Bortezomib Injection, powder, lyophilized, for solution 1 mg/mL Intravenous Fresenius Kabi 2017-11-06 Not applicable US 
Bortezomib for Injection Powder, for solution 3.5 mg Intravenous; Subcutaneous Pfizer Not applicable Not applicable Canada Bortezomib for Injection Powder, for solution 3.5 mg Intravenous; Subcutaneous Dr Reddy's Laboratories 2017-03-21 Not applicable Canada Bortezomib for Injection Powder, for solution 3.5 mg Intravenous; Subcutaneous Teva 2015-01-06 Not applicable Canada Bortezomib for Injection Powder, for solution 2.5 mg Intravenous; Subcutaneous Pfizer Not applicable Not applicable Canada Bortezomib for Injection Powder, for solution 3.5 mg Intravenous; Subcutaneous Sandoz Canada Incorporated Not applicable Not applicable Canada Velcade Powder, for solution 3.5 mg Intravenous; Subcutaneous Janssen Pharmaceuticals 2005-02-01 Not applicable Canada Velcade Injection, powder, lyophilized, for solution 3.5 mg/1 Intravenous; Subcutaneous Millennium Pharmaceuticals, Inc. 2003-05-13 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Bortezomib Accord Injection, powder, for solution 3.5 mg Intravenous; Subcutaneous Accord Healthcare Limited 2015-07-20 Not applicable EU 
Bortezomib Hospira Injection, powder, for solution 3.5 mg Intravenous; Subcutaneous Hospira, Inc. 2016-07-22 Not applicable EU Bortezomib Sun Injection, powder, for solution 3.5 mg Intravenous; Subcutaneous Sun Pharmaceutical Industries (Europe) B.V. 2016-07-22 Not applicable EU PMS-bortezomib Powder, for solution 3.5 mg Intravenous; Subcutaneous Pharmascience Inc Not applicable Not applicable Canada - Categories
- Acids
- Acids, Noncarboxylic
- Antineoplastic Agents
- Antineoplastic and Immunomodulating Agents
- Boron Compounds
- Boronic Acids
- Cardiotoxic antineoplastic agents
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors (moderate)
- Cytochrome P-450 CYP1A2 Substrates
- Cytochrome P-450 CYP2C19 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors (moderate)
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (weak)
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A4 Substrates (strength unknown)
- Cytochrome P-450 Enzyme Inhibitors
- Hypotensive Agents
- Immunosuppressive Agents
- Myelosuppressive Agents
- Potential QTc-Prolonging Agents
- Proteasome Inhibitors
- Pyrazines
- QTc Prolonging Agents
- UNII
- 69G8BD63PP
- CAS number
- 179324-69-7
- Weight
- Average: 384.237
Monoisotopic: 384.196885774 - Chemical Formula
- C19H25BN4O4
- InChI Key
- GXJABQQUPOEUTA-RDJZCZTQSA-N
- InChI
- InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
- IUPAC Name
- [(1R)-3-methyl-1-[(2S)-3-phenyl-2-(pyrazin-2-ylformamido)propanamido]butyl]boronic acid
- SMILES
- CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
Pharmacology
- Indication
For treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies.
- Associated Conditions
- Pharmacodynamics
Bortezomib is a drug that inhibits the mammalian 26S proteasome. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma. Tumor cells, that is, rapidly dividing cells, appear to be more sensitive to proteasome inhibition.
- Mechanism of action
Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The active site of the proteasome has chymotrypsin-like, trypsin-like, and postglutamyl peptide hydrolysis activity. The 26S proteasome degrades various proteins critical to cancer cell survival, such as cyclins, tumor suppressors, BCL-2, and cyclin-dependent kinase inhibitors. Inhibition of these degradations sensitizes cells to apoptosis. Bortezomib is a potent inhibitor of 26S proteasome, which sensitizes activity in dividing multiple myeloma and leukemic cells, thus inducing apoptosis. In addition, bortezomib appears to increase the sensitivity of cancer cells to traditional anticancer agents (e.g., gemcitabine, cisplatin, paclitaxel, irinotecan, and radiation).
Target Actions Organism AProteasome subunit beta type-5 inhibitorHuman AProteasome subunit beta type-1 inhibitorHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
83% over the concentration range of 100-1000 ng/ml.
- Metabolism
In vitro studies with human liver microsomes and human cDNA-expressed cytochrome P450 isozymes indicate that bortezomib is primarily oxidatively metabolized via cytochrome P450 enzymes 3A4, 2C19, and 1A2, while bortezomib metabolism by CYP 2D6 and 2C9 enzymes is minor. The major metabolic pathway is deboronation to form 2 deboronated metabolites that subsequently undergo hydroxylation to several metabolites which are inactive as 26S proteasome inhibitors.
- Route of elimination
The pathways of elimination of bortezomib have not been characterized in humans.
- Half life
The mean elimination half-life of bortezomib after first dose ranged from 9 to 15 hours at doses ranging from 1.45 to 2.00 mg/m2 in patients with advanced malignancies.
- Clearance
- 102 L/h [patients with multiple myeloma following the first dose for doses of 1 mg/m2]
- 112 L/h [patients with multiple myeloma following the first dose for doses of 1.3 mg/m2]
- 15 - 32 L/h [patients with multiple myeloma following subsequent doses for doses of 1 and 1.3 mg/m2]
- Toxicity
Cardiovascular safety pharmacology studies in monkeys show that lethal IV doses are associated with decreases in blood pressure, increases in heart rate, increases in contractility, and ultimately terminal hypotension. In monkeys, doses of 3.0 mg/m2 and greater (approximately twice the recommended clinical dose) resulted in progressive hypotension starting at 1 hour and progressing to death by 12 to 14 hours following drug administration.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Bortezomib. Approved, Investigational Abiraterone The serum concentration of Bortezomib can be increased when it is combined with Abiraterone. Approved Acebutolol The risk or severity of adverse effects can be increased when Bortezomib is combined with Acebutolol. Approved, Investigational Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Bortezomib. Approved, Investigational Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Bortezomib. Approved Acetyl sulfisoxazole The metabolism of Bortezomib can be decreased when combined with Acetyl sulfisoxazole. Approved, Vet Approved Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Bortezomib. Approved Acetyldigoxin Acetyldigoxin may decrease the cardiotoxic activities of Bortezomib. Experimental Adinazolam The metabolism of Adinazolam can be decreased when combined with Bortezomib. Approved Agomelatine The serum concentration of Agomelatine can be increased when it is combined with Bortezomib. Approved, Investigational Albendazole The metabolism of Albendazole can be decreased when combined with Bortezomib. Approved, Vet Approved Alclometasone The metabolism of Alclometasone can be decreased when combined with Bortezomib. Approved Aldesleukin The risk or severity of adverse effects can be increased when Bortezomib is combined with Aldesleukin. Approved Alfentanil The metabolism of Alfentanil can be decreased when combined with Bortezomib. Approved, Illicit Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Bortezomib. Approved, Investigational Aliskiren The metabolism of Aliskiren can be decreased when combined with Bortezomib. Approved, Investigational Allylestrenol The metabolism of Allylestrenol can be decreased when combined with Bortezomib. Approved Almotriptan The metabolism of Almotriptan can be decreased when combined with Bortezomib. Approved, Investigational Alogliptin The metabolism of Alogliptin can be decreased when combined with Bortezomib. Approved Alosetron The metabolism of Alosetron can be decreased when combined with Bortezomib. Approved, Withdrawn alpha-Tocopherol acetate The metabolism of alpha-Tocopherol acetate can be decreased when combined with Bortezomib. Approved Alprazolam The metabolism of Alprazolam can be decreased when combined with Bortezomib. Approved, Illicit, Investigational Ambrisentan The metabolism of Ambrisentan can be decreased when combined with Bortezomib. Approved, Investigational Ambroxol The metabolism of Ambroxol can be decreased when combined with Bortezomib. Approved, Investigational Amifostine The risk or severity of adverse effects can be increased when Amifostine is combined with Bortezomib. Approved, Investigational Amiloride The risk or severity of adverse effects can be increased when Bortezomib is combined with Amiloride. Approved Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Bortezomib. Approved, Withdrawn Aminophylline The metabolism of Aminophylline can be decreased when combined with Bortezomib. Approved Amiodarone The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Amiodarone. Approved, Investigational Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Bortezomib. Approved Amlodipine The risk or severity of adverse effects can be increased when Bortezomib is combined with Amlodipine. Approved Amobarbital Amobarbital may increase the hypotensive activities of Bortezomib. Approved, Illicit Amphotericin B The risk or severity of adverse effects can be increased when Amphotericin B is combined with Bortezomib. Approved, Investigational Amprenavir The metabolism of Amprenavir can be decreased when combined with Bortezomib. Approved, Investigational Amyl Nitrite The risk or severity of adverse effects can be increased when Bortezomib is combined with Amyl Nitrite. Approved Anagrelide Bortezomib may increase the QTc-prolonging activities of Anagrelide. Approved Ancestim The risk or severity of cytotoxicity can be increased when Ancestim is combined with Bortezomib. Approved, Investigational, Withdrawn Antipyrine The metabolism of Antipyrine can be decreased when combined with Bortezomib. Approved, Investigational Apalutamide The serum concentration of Bortezomib can be decreased when it is combined with Apalutamide. Approved, Investigational Apixaban The serum concentration of Apixaban can be increased when it is combined with Bortezomib. Approved Apomorphine The risk or severity of adverse effects can be increased when Apomorphine is combined with Bortezomib. Approved, Investigational Apraclonidine The risk or severity of adverse effects can be increased when Bortezomib is combined with Apraclonidine. Approved Apremilast The metabolism of Apremilast can be decreased when combined with Bortezomib. Approved, Investigational Aprepitant The serum concentration of Bortezomib can be increased when it is combined with Aprepitant. Approved, Investigational Argatroban The metabolism of Argatroban can be decreased when combined with Bortezomib. Approved, Investigational Aripiprazole The serum concentration of Aripiprazole can be increased when it is combined with Bortezomib. Approved, Investigational Armodafinil The metabolism of Bortezomib can be decreased when combined with Armodafinil. Approved, Investigational Arotinolol The risk or severity of adverse effects can be increased when Arotinolol is combined with Bortezomib. Investigational Arsenic trioxide Bortezomib may increase the QTc-prolonging activities of Arsenic trioxide. Approved, Investigational Artemether Bortezomib may increase the QTc-prolonging activities of Artemether. Approved Ascorbic acid The therapeutic efficacy of Bortezomib can be decreased when used in combination with Vitamin C. Approved, Nutraceutical Asenapine Bortezomib may increase the QTc-prolonging activities of Asenapine. Approved Astemizole The metabolism of Astemizole can be decreased when combined with Bortezomib. Approved, Withdrawn Asunaprevir The serum concentration of Asunaprevir can be increased when it is combined with Bortezomib. Approved, Investigational, Withdrawn Atazanavir The serum concentration of Bortezomib can be increased when it is combined with Atazanavir. Approved, Investigational Atenolol The risk or severity of adverse effects can be increased when Bortezomib is combined with Atenolol. Approved Atomoxetine The metabolism of Bortezomib can be decreased when combined with Atomoxetine. Approved Atorvastatin The risk or severity of adverse effects can be increased when Bortezomib is combined with Atorvastatin. Approved Avanafil The serum concentration of Avanafil can be increased when it is combined with Bortezomib. Approved Avatrombopag The metabolism of Avatrombopag can be decreased when combined with Bortezomib. Approved, Investigational Axitinib The metabolism of Axitinib can be decreased when combined with Bortezomib. Approved, Investigational Azelastine The metabolism of Azelastine can be decreased when combined with Bortezomib. Approved Azilsartan medoxomil The risk or severity of adverse effects can be increased when Bortezomib is combined with Azilsartan medoxomil. Approved, Investigational Azithromycin The metabolism of Azithromycin can be decreased when combined with Bortezomib. Approved Banoxantrone The metabolism of Banoxantrone can be decreased when combined with Bortezomib. Investigational Barbexaclone Barbexaclone may increase the hypotensive activities of Bortezomib. Experimental Barbital Barbital may increase the hypotensive activities of Bortezomib. Illicit Baricitinib The metabolism of Baricitinib can be decreased when combined with Bortezomib. Approved, Investigational Barnidipine The risk or severity of adverse effects can be increased when Barnidipine is combined with Bortezomib. Approved Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Bortezomib is combined with Beclomethasone dipropionate. Approved, Investigational Bedaquiline The metabolism of Bedaquiline can be decreased when combined with Bortezomib. Approved Benazepril The risk or severity of adverse effects can be increased when Bortezomib is combined with Benazepril. Approved, Investigational Bendamustine The metabolism of Bendamustine can be decreased when combined with Bortezomib. Approved, Investigational Bendroflumethiazide The risk or severity of adverse effects can be increased when Bortezomib is combined with Bendroflumethiazide. Approved Benzatropine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Benzatropine. Approved Bepridil The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Bepridil. Approved, Withdrawn Betaxolol The metabolism of Betaxolol can be decreased when combined with Bortezomib. Approved, Investigational Bevacizumab Bevacizumab may increase the cardiotoxic activities of Bortezomib. Approved, Investigational Bexarotene The metabolism of Bexarotene can be decreased when combined with Bortezomib. Approved, Investigational Bezafibrate The metabolism of Bezafibrate can be decreased when combined with Bortezomib. Approved, Investigational Bicalutamide The metabolism of Bicalutamide can be decreased when combined with Bortezomib. Approved Bictegravir The metabolism of Bictegravir can be decreased when combined with Bortezomib. Approved, Investigational Bisoprolol The metabolism of Bisoprolol can be decreased when combined with Bortezomib. Approved Blonanserin The metabolism of Blonanserin can be decreased when combined with Bortezomib. Approved, Investigational Boceprevir The serum concentration of Bortezomib can be increased when it is combined with Boceprevir. Approved, Withdrawn Bosentan The serum concentration of Bosentan can be increased when it is combined with Bortezomib. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Bortezomib. Approved Brentuximab vedotin The metabolism of Brentuximab vedotin can be decreased when combined with Bortezomib. Approved, Investigational Bretylium The risk or severity of adverse effects can be increased when Bortezomib is combined with Bretylium. Approved Brexpiprazole The serum concentration of Brexpiprazole can be increased when it is combined with Bortezomib. Approved, Investigational Brigatinib The metabolism of Brigatinib can be decreased when combined with Bortezomib. Approved, Investigational Brimonidine The risk or severity of adverse effects can be increased when Bortezomib is combined with Brimonidine. Approved Brinzolamide The metabolism of Brinzolamide can be decreased when combined with Bortezomib. Approved Brivaracetam The metabolism of Brivaracetam can be decreased when combined with Bortezomib. Approved, Investigational Bromazepam The metabolism of Bromazepam can be decreased when combined with Bortezomib. Approved, Illicit, Investigational Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Bortezomib. Approved, Investigational Brompheniramine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Brompheniramine. Approved Budesonide The risk or severity of adverse effects can be increased when Budesonide is combined with Bortezomib. Approved Bumetanide The risk or severity of adverse effects can be increased when Bortezomib is combined with Bumetanide. Approved Bupivacaine The metabolism of Bupivacaine can be decreased when combined with Bortezomib. Approved, Investigational Buprenorphine The metabolism of Buprenorphine can be decreased when combined with Bortezomib. Approved, Illicit, Investigational, Vet Approved Buspirone The metabolism of Buspirone can be decreased when combined with Bortezomib. Approved, Investigational Busulfan The metabolism of Busulfan can be decreased when combined with Bortezomib. Approved, Investigational Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bortezomib. Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Bortezomib. Approved Cabozantinib The metabolism of Cabozantinib can be decreased when combined with Bortezomib. Approved, Investigational Caffeine The metabolism of Caffeine can be decreased when combined with Bortezomib. Approved Calcitriol The metabolism of Calcitriol can be decreased when combined with Bortezomib. Approved, Nutraceutical Canagliflozin The metabolism of Canagliflozin can be decreased when combined with Bortezomib. Approved Candesartan cilexetil The risk or severity of adverse effects can be increased when Bortezomib is combined with Candesartan cilexetil. Approved Cannabidiol The metabolism of Cannabidiol can be decreased when combined with Bortezomib. Approved, Investigational Capecitabine The metabolism of Bortezomib can be decreased when combined with Capecitabine. Approved, Investigational Captopril The risk or severity of adverse effects can be increased when Bortezomib is combined with Captopril. Approved Carbamazepine The serum concentration of Bortezomib can be decreased when it is combined with Carbamazepine. Approved, Investigational Carbetocin The risk or severity of adverse effects can be increased when Bortezomib is combined with Carbetocin. Approved, Investigational Carbinoxamine The metabolism of Carbinoxamine can be decreased when combined with Bortezomib. Approved Cariprazine The metabolism of Cariprazine can be decreased when combined with Bortezomib. Approved, Investigational Carmustine The metabolism of Carmustine can be decreased when combined with Bortezomib. Approved, Investigational Carteolol The risk or severity of adverse effects can be increased when Bortezomib is combined with Carteolol. Approved Carvedilol The risk or severity of adverse effects can be increased when Bortezomib is combined with Carvedilol. Approved, Investigational Celecoxib The metabolism of Celecoxib can be decreased when combined with Bortezomib. Approved, Investigational Celiprolol The metabolism of Celiprolol can be decreased when combined with Bortezomib. Approved, Investigational Cephalexin The metabolism of Cephalexin can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Ceritinib The serum concentration of Bortezomib can be increased when it is combined with Ceritinib. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Bortezomib. Approved, Withdrawn Cetirizine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Cetirizine. Approved Cevimeline The metabolism of Cevimeline can be decreased when combined with Bortezomib. Approved Chenodeoxycholic acid The metabolism of Chenodeoxycholic acid can be decreased when combined with Bortezomib. Approved Chloramphenicol The metabolism of Bortezomib can be decreased when combined with Chloramphenicol. Approved, Vet Approved Chlordiazepoxide The metabolism of Chlordiazepoxide can be decreased when combined with Bortezomib. Approved, Illicit, Investigational Chloroquine The metabolism of Chloroquine can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Chlorothiazide The risk or severity of adverse effects can be increased when Bortezomib is combined with Chlorothiazide. Approved, Vet Approved Chlorphenamine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Chlorphenamine. Approved Chlorpromazine The risk or severity of adverse effects can be increased when Bortezomib is combined with Chlorpromazine. Approved, Investigational, Vet Approved Chlorthalidone The risk or severity of adverse effects can be increased when Bortezomib is combined with Chlorthalidone. Approved Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Bortezomib. Approved Cholecalciferol The metabolism of Cholecalciferol can be decreased when combined with Bortezomib. Approved, Nutraceutical Ciclesonide The metabolism of Ciclesonide can be decreased when combined with Bortezomib. Approved, Investigational Cilazapril The risk or severity of adverse effects can be increased when Bortezomib is combined with Cilazapril. Approved Cilnidipine The risk or severity of adverse effects can be increased when Bortezomib is combined with Cilnidipine. Approved, Investigational Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Bortezomib. Approved, Investigational Cinacalcet The metabolism of Bortezomib can be decreased when combined with Cinacalcet. Approved Cinnarizine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Cinnarizine. Approved, Investigational Ciprofloxacin The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ciprofloxacin. Approved, Investigational Cisapride Bortezomib may increase the QTc-prolonging activities of Cisapride. Approved, Investigational, Withdrawn Citalopram The serum concentration of Citalopram can be increased when it is combined with Bortezomib. Approved Clarithromycin The serum concentration of Bortezomib can be increased when it is combined with Clarithromycin. Approved Clemastine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Clemastine. Approved, Investigational Clenbuterol The metabolism of Clenbuterol can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Clevidipine The risk or severity of adverse effects can be increased when Bortezomib is combined with Clevidipine. Approved, Investigational Clobazam The metabolism of Clobazam can be decreased when combined with Bortezomib. Approved, Illicit Clofarabine The risk or severity of adverse effects can be increased when Bortezomib is combined with Clofarabine. Approved, Investigational Clofazimine The metabolism of Clofazimine can be decreased when combined with Bortezomib. Approved, Investigational Clofibrate The metabolism of Clofibrate can be decreased when combined with Bortezomib. Approved, Investigational clomethiazole The metabolism of clomethiazole can be decreased when combined with Bortezomib. Investigational Clomipramine The metabolism of Clomipramine can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Clonazepam The metabolism of Clonazepam can be decreased when combined with Bortezomib. Approved, Illicit Clonidine The metabolism of Clonidine can be decreased when combined with Bortezomib. Approved Clopidogrel The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Bortezomib resulting in a loss in efficacy. Approved Clorazepate The metabolism of Clorazepate can be decreased when combined with Bortezomib. Approved, Illicit Clotiazepam The metabolism of Clotiazepam can be decreased when combined with Bortezomib. Approved, Illicit Clotrimazole The serum concentration of Bortezomib can be increased when it is combined with Clotrimazole. Approved, Vet Approved Clozapine The risk or severity of adverse effects can be increased when Bortezomib is combined with Clozapine. Approved Cobicistat The serum concentration of Bortezomib can be increased when it is combined with Cobicistat. Approved Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Bortezomib. Approved, Investigational Cocaine The metabolism of Bortezomib can be decreased when combined with Cocaine. Approved, Illicit Colchicine The serum concentration of Colchicine can be increased when it is combined with Bortezomib. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Bortezomib. Approved, Investigational Conjugated estrogens The metabolism of Conjugated estrogens can be decreased when combined with Bortezomib. Approved Copanlisib The metabolism of Copanlisib can be decreased when combined with Bortezomib. Approved, Investigational Cortisone acetate The metabolism of Cortisone acetate can be decreased when combined with Bortezomib. Approved, Investigational Crisaborole The metabolism of Bortezomib can be decreased when combined with Crisaborole. Approved, Investigational Crizotinib The metabolism of Crizotinib can be decreased when combined with Bortezomib. Approved Curcumin The serum concentration of Bortezomib can be increased when it is combined with Curcumin. Approved, Investigational Cyclophosphamide Cyclophosphamide may increase the cardiotoxic activities of Bortezomib. Approved, Investigational Cyclosporine The risk or severity of adverse effects can be increased when Cyclosporine is combined with Bortezomib. Approved, Investigational, Vet Approved Cymarin Cymarin may decrease the cardiotoxic activities of Bortezomib. Experimental Cyproterone acetate The serum concentration of Bortezomib can be decreased when it is combined with Cyproterone acetate. Approved, Investigational Cytarabine The metabolism of Cytarabine can be decreased when combined with Bortezomib. Approved, Investigational Dabrafenib The serum concentration of Bortezomib can be decreased when it is combined with Dabrafenib. Approved, Investigational Dacarbazine The metabolism of Dacarbazine can be decreased when combined with Bortezomib. Approved, Investigational Daclatasvir The metabolism of Daclatasvir can be decreased when combined with Bortezomib. Approved, Investigational Dantrolene The metabolism of Dantrolene can be decreased when combined with Bortezomib. Approved, Investigational Dapagliflozin The risk or severity of adverse effects can be increased when Bortezomib is combined with Dapagliflozin. Approved Dapoxetine The serum concentration of Dapoxetine can be increased when it is combined with Bortezomib. Investigational Dapsone The metabolism of Dapsone can be decreased when combined with Bortezomib. Approved, Investigational Darifenacin The metabolism of Darifenacin can be decreased when combined with Bortezomib. Approved, Investigational Darunavir The serum concentration of Bortezomib can be increased when it is combined with Darunavir. Approved Dasabuvir The metabolism of Dasabuvir can be decreased when combined with Bortezomib. Approved Dasatinib The serum concentration of Bortezomib can be increased when it is combined with Dasatinib. Approved, Investigational Daunorubicin The metabolism of Daunorubicin can be decreased when combined with Bortezomib. Approved Deferasirox The serum concentration of Bortezomib can be decreased when it is combined with Deferasirox. Approved, Investigational Deflazacort The metabolism of Deflazacort can be decreased when combined with Bortezomib. Approved, Investigational Delamanid The metabolism of Delamanid can be decreased when combined with Bortezomib. Approved, Investigational Delavirdine The metabolism of Bortezomib can be decreased when combined with Delavirdine. Approved Desflurane The risk or severity of adverse effects can be increased when Bortezomib is combined with Desflurane. Approved Desipramine The metabolism of Desipramine can be decreased when combined with Bortezomib. Approved, Investigational Deslanoside Deslanoside may decrease the cardiotoxic activities of Bortezomib. Approved Deutetrabenazine The metabolism of Deutetrabenazine can be decreased when combined with Bortezomib. Approved, Investigational Dexamethasone The risk or severity of adverse effects can be increased when Dexamethasone is combined with Bortezomib. Approved, Investigational, Vet Approved Dexbrompheniramine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Dexbrompheniramine. Approved Dexchlorpheniramine maleate The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Bortezomib. Approved Dexfenfluramine The metabolism of Dexfenfluramine can be decreased when combined with Bortezomib. Approved, Illicit, Investigational, Withdrawn Dexlansoprazole The metabolism of Dexlansoprazole can be decreased when combined with Bortezomib. Approved, Investigational Dexmedetomidine The risk or severity of adverse effects can be increased when Bortezomib is combined with Dexmedetomidine. Approved, Vet Approved Dextropropoxyphene The metabolism of Dextropropoxyphene can be decreased when combined with Bortezomib. Approved, Illicit, Investigational, Withdrawn Diazepam The metabolism of Diazepam can be decreased when combined with Bortezomib. Approved, Illicit, Investigational, Vet Approved Diclofenac The metabolism of Diclofenac can be decreased when combined with Bortezomib. Approved, Vet Approved Diclofenamide The risk or severity of adverse effects can be increased when Bortezomib is combined with Diclofenamide. Approved, Investigational Dienogest The metabolism of Dienogest can be decreased when combined with Bortezomib. Approved Digitoxin Digitoxin may decrease the cardiotoxic activities of Bortezomib. Approved, Investigational Digoxin Digoxin may decrease the cardiotoxic activities of Bortezomib. Approved Digoxin Immune Fab (Ovine) Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Bortezomib. Approved Dihydro-alpha-ergocryptine The metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Bortezomib. Approved Dihydrocodeine The metabolism of Dihydrocodeine can be decreased when combined with Bortezomib. Approved, Illicit Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Bortezomib. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Bortezomib. Approved, Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Bortezomib. Experimental Dihydroergotamine The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Bortezomib. Approved, Investigational Diltiazem The serum concentration of Bortezomib can be increased when it is combined with Diltiazem. Approved, Investigational Dimenhydrinate The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Dimenhydrinate. Approved Dinoprostone The metabolism of Dinoprostone can be decreased when combined with Bortezomib. Approved Dinutuximab The risk or severity of adverse effects can be increased when Bortezomib is combined with Dinutuximab. Approved, Investigational Diphenhydramine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Diphenhydramine. Approved, Investigational Dipyridamole The risk or severity of adverse effects can be increased when Bortezomib is combined with Dipyridamole. Approved Disopyramide Bortezomib may increase the QTc-prolonging activities of Disopyramide. Approved Disulfiram The metabolism of Disulfiram can be decreased when combined with Bortezomib. Approved Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Bortezomib. Approved, Investigational Dofetilide The serum concentration of Dofetilide can be increased when it is combined with Bortezomib. Approved, Investigational Dolasetron The metabolism of Dolasetron can be decreased when combined with Bortezomib. Approved, Investigational Domperidone The serum concentration of Domperidone can be increased when it is combined with Bortezomib. Approved, Investigational, Vet Approved Donepezil The metabolism of Donepezil can be decreased when combined with Bortezomib. Approved Dorzolamide The metabolism of Dorzolamide can be decreased when combined with Bortezomib. Approved Dosulepin The metabolism of Bortezomib can be decreased when combined with Dosulepin. Approved Doxazosin The risk or severity of adverse effects can be increased when Bortezomib is combined with Doxazosin. Approved Doxepin The metabolism of Doxepin can be decreased when combined with Bortezomib. Approved, Investigational Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Bortezomib. Approved, Investigational Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Bortezomib. Approved, Investigational Doxycycline The metabolism of Bortezomib can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Doxylamine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Doxylamine. Approved, Vet Approved Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Bortezomib. Approved, Illicit Dronedarone Bortezomib may increase the QTc-prolonging activities of Dronedarone. Approved Droperidol Bortezomib may increase the QTc-prolonging activities of Droperidol. Approved, Vet Approved Duloxetine Bortezomib may increase the orthostatic hypotensive activities of Duloxetine. Approved Dutasteride The metabolism of Dutasteride can be decreased when combined with Bortezomib. Approved, Investigational Efavirenz The metabolism of Efavirenz can be decreased when combined with Bortezomib. Approved, Investigational Efonidipine The risk or severity of adverse effects can be increased when Bortezomib is combined with Efonidipine. Approved, Investigational Elbasvir The metabolism of Elbasvir can be decreased when combined with Bortezomib. Approved Eletriptan The serum concentration of Eletriptan can be increased when it is combined with Bortezomib. Approved, Investigational Eliglustat The serum concentration of Eliglustat can be increased when it is combined with Bortezomib. Approved Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Bortezomib. Approved Elvitegravir The metabolism of Elvitegravir can be decreased when combined with Bortezomib. Approved Empagliflozin The risk or severity of adverse effects can be increased when Bortezomib is combined with Empagliflozin. Approved Enalapril The metabolism of Enalapril can be decreased when combined with Bortezomib. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when Bortezomib is combined with Enalaprilat. Approved Enasidenib The metabolism of Enasidenib can be decreased when combined with Bortezomib. Approved, Investigational Enzalutamide The serum concentration of Bortezomib can be decreased when it is combined with Enzalutamide. Approved Epinastine The metabolism of Epinastine can be decreased when combined with Bortezomib. Approved, Investigational Eplerenone The serum concentration of Eplerenone can be increased when it is combined with Bortezomib. Approved Epoprostenol The risk or severity of adverse effects can be increased when Bortezomib is combined with Epoprostenol. Approved Eprosartan The risk or severity of adverse effects can be increased when Bortezomib is combined with Eprosartan. Approved Ergocalciferol The metabolism of Ergocalciferol can be decreased when combined with Bortezomib. Approved, Nutraceutical Ergoloid mesylate The metabolism of Ergoloid mesylate can be decreased when combined with Bortezomib. Approved Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Bortezomib. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Bortezomib. Approved Erlotinib The metabolism of Erlotinib can be decreased when combined with Bortezomib. Approved, Investigational Erythromycin The metabolism of Erythromycin can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Escitalopram Bortezomib may increase the QTc-prolonging activities of Escitalopram. Approved, Investigational Eslicarbazepine acetate The metabolism of Bortezomib can be decreased when combined with Eslicarbazepine acetate. Approved Esmolol The risk or severity of adverse effects can be increased when Bortezomib is combined with Esmolol. Approved Esomeprazole The metabolism of Esomeprazole can be decreased when combined with Bortezomib. Approved, Investigational Estazolam The metabolism of Estazolam can be decreased when combined with Bortezomib. Approved, Illicit Estradiol The metabolism of Estradiol can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Estradiol acetate The metabolism of Estradiol acetate can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Estradiol benzoate The metabolism of Estradiol benzoate can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Estradiol valerate The metabolism of Estradiol valerate can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Estramustine The metabolism of Estramustine can be decreased when combined with Bortezomib. Approved, Investigational Estrogens, esterified The metabolism of Estrogens, esterified can be decreased when combined with Bortezomib. Approved Estrone The metabolism of Estrone can be decreased when combined with Bortezomib. Approved Estrone sulfate The metabolism of Estrone sulfate can be decreased when combined with Bortezomib. Approved Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Bortezomib. Approved, Investigational Etacrynic acid The risk or severity of adverse effects can be increased when Bortezomib is combined with Etacrynic acid. Approved, Investigational Ethanol The metabolism of Ethanol can be decreased when combined with Bortezomib. Approved Ethylmorphine The metabolism of Ethylmorphine can be decreased when combined with Bortezomib. Approved, Illicit Etizolam The metabolism of Etizolam can be decreased when combined with Bortezomib. Approved Etonogestrel The metabolism of Etonogestrel can be decreased when combined with Bortezomib. Approved, Investigational Etoposide The metabolism of Etoposide can be decreased when combined with Bortezomib. Approved Etoricoxib The metabolism of Etoricoxib can be decreased when combined with Bortezomib. Approved, Investigational Etravirine The metabolism of Etravirine can be decreased when combined with Bortezomib. Approved Everolimus The risk or severity of adverse effects can be increased when Everolimus is combined with Bortezomib. Approved Exemestane The metabolism of Exemestane can be decreased when combined with Bortezomib. Approved, Investigational Famciclovir The metabolism of Famciclovir can be decreased when combined with Bortezomib. Approved, Investigational Famotidine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Famotidine. Approved Felbamate The metabolism of Felbamate can be decreased when combined with Bortezomib. Approved Felodipine The risk or severity of adverse effects can be increased when Bortezomib is combined with Felodipine. Approved, Investigational Fenofibrate The metabolism of Fenofibrate can be decreased when combined with Bortezomib. Approved Fenoldopam The risk or severity of adverse effects can be increased when Bortezomib is combined with Fenoldopam. Approved Fesoterodine The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bortezomib. Approved Fimasartan The risk or severity of adverse effects can be increased when Bortezomib is combined with Fimasartan. Approved, Investigational Finasteride The metabolism of Finasteride can be decreased when combined with Bortezomib. Approved Fingolimod The metabolism of Fingolimod can be decreased when combined with Bortezomib. Approved, Investigational Flecainide Bortezomib may increase the QTc-prolonging activities of Flecainide. Approved, Withdrawn Flibanserin The risk or severity of adverse effects can be increased when Bortezomib is combined with Flibanserin. Approved, Investigational Floxuridine The metabolism of Bortezomib can be decreased when combined with Floxuridine. Approved Fluconazole The metabolism of Bortezomib can be decreased when combined with Fluconazole. Approved, Investigational Flunarizine The metabolism of Flunarizine can be decreased when combined with Bortezomib. Approved Flunisolide The metabolism of Flunisolide can be decreased when combined with Bortezomib. Approved, Investigational Flunitrazepam The metabolism of Flunitrazepam can be decreased when combined with Bortezomib. Approved, Illicit Fluorometholone The metabolism of Fluorometholone can be decreased when combined with Bortezomib. Approved, Investigational Fluorouracil The metabolism of Bortezomib can be decreased when combined with Fluorouracil. Approved Fluoxetine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Fluoxetine. Approved, Vet Approved Flupentixol Bortezomib may increase the QTc-prolonging activities of Flupentixol. Approved, Investigational, Withdrawn Flurazepam The metabolism of Flurazepam can be decreased when combined with Bortezomib. Approved, Illicit, Investigational Flutamide The metabolism of Flutamide can be decreased when combined with Bortezomib. Approved, Investigational Fluticasone furoate The metabolism of Fluticasone furoate can be decreased when combined with Bortezomib. Approved Fluticasone propionate The risk or severity of adverse effects can be increased when Bortezomib is combined with Fluticasone propionate. Approved Fluvoxamine The metabolism of Bortezomib can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Fosamprenavir can be decreased when combined with Bortezomib. Approved Fosaprepitant The serum concentration of Bortezomib can be increased when it is combined with Fosaprepitant. Approved Fosinopril The risk or severity of adverse effects can be increased when Bortezomib is combined with Fosinopril. Approved Fosnetupitant The metabolism of Fosnetupitant can be decreased when combined with Bortezomib. Approved Fosphenytoin The serum concentration of Bortezomib can be decreased when it is combined with Fosphenytoin. Approved, Investigational Fostamatinib The metabolism of Fostamatinib can be decreased when combined with Bortezomib. Approved, Investigational Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Bortezomib. Approved, Investigational Fulvestrant The metabolism of Fulvestrant can be decreased when combined with Bortezomib. Approved, Investigational Furosemide The risk or severity of adverse effects can be increased when Bortezomib is combined with Furosemide. Approved, Vet Approved Fusidic Acid The serum concentration of Bortezomib can be increased when it is combined with Fusidic Acid. Approved, Investigational Gadobenic acid Bortezomib may increase the QTc-prolonging activities of Gadobenic acid. Approved, Investigational Galantamine The metabolism of Galantamine can be decreased when combined with Bortezomib. Approved Gefitinib The metabolism of Gefitinib can be decreased when combined with Bortezomib. Approved, Investigational Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Bortezomib. Approved Gemfibrozil The metabolism of Bortezomib can be decreased when combined with Gemfibrozil. Approved Gemifloxacin Bortezomib may increase the QTc-prolonging activities of Gemifloxacin. Approved, Investigational Genistein The metabolism of Genistein can be decreased when combined with Bortezomib. Investigational Gitoformate Gitoformate may decrease the cardiotoxic activities of Bortezomib. Experimental Goserelin Bortezomib may increase the QTc-prolonging activities of Goserelin. Approved Granisetron The metabolism of Granisetron can be decreased when combined with Bortezomib. Approved, Investigational Grazoprevir The metabolism of Grazoprevir can be decreased when combined with Bortezomib. Approved Grepafloxacin The metabolism of Grepafloxacin can be decreased when combined with Bortezomib. Approved, Investigational, Withdrawn Guanabenz The metabolism of Guanabenz can be decreased when combined with Bortezomib. Approved, Investigational Guanfacine The risk or severity of adverse effects can be increased when Bortezomib is combined with Guanfacine. Approved, Investigational Halofantrine The serum concentration of Halofantrine can be increased when it is combined with Bortezomib. Approved Haloperidol The metabolism of Haloperidol can be decreased when combined with Bortezomib. Approved Halothane The metabolism of Halothane can be decreased when combined with Bortezomib. Approved, Vet Approved Hesperetin The metabolism of Hesperetin can be decreased when combined with Bortezomib. Approved Hexobarbital The metabolism of Hexobarbital can be decreased when combined with Bortezomib. Approved Hydralazine The risk or severity of adverse effects can be increased when Bortezomib is combined with Hydralazine. Approved Hydrochlorothiazide The risk or severity of adverse effects can be increased when Bortezomib is combined with Hydrochlorothiazide. Approved, Vet Approved Hydrocodone The metabolism of Hydrocodone can be decreased when combined with Bortezomib. Approved, Illicit Hydrocortisone The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Bortezomib. Approved, Vet Approved Hydrocortisone acetate The risk or severity of adverse effects can be increased when Bortezomib is combined with Hydrocortisone acetate. Approved, Vet Approved Hydrocortisone butyrate The risk or severity of adverse effects can be increased when Bortezomib is combined with Hydrocortisone butyrate. Approved, Vet Approved Hydroflumethiazide The risk or severity of adverse effects can be increased when Bortezomib is combined with Hydroflumethiazide. Approved, Investigational Hydromorphone The metabolism of Hydromorphone can be decreased when combined with Bortezomib. Approved, Illicit Hydroxyprogesterone caproate The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Bortezomib. Approved, Investigational Hydroxyzine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Hydroxyzine. Approved Ibandronate The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ibandronate. Approved, Investigational Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Bortezomib. Approved Ibutilide Bortezomib may increase the QTc-prolonging activities of Ibutilide. Approved Icotinib The metabolism of Icotinib can be decreased when combined with Bortezomib. Approved, Investigational Idelalisib The serum concentration of Bortezomib can be increased when it is combined with Idelalisib. Approved Ifosfamide The serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Bortezomib resulting in a loss in efficacy. Approved Iloperidone Bortezomib may increase the QTc-prolonging activities of Iloperidone. Approved Iloprost The risk or severity of adverse effects can be increased when Bortezomib is combined with Iloprost. Approved, Investigational Imatinib The serum concentration of Imatinib can be increased when it is combined with Bortezomib. Approved Imidafenacin The metabolism of Imidafenacin can be decreased when combined with Bortezomib. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Bortezomib is combined with Imidapril. Investigational Imipramine The metabolism of Imipramine can be decreased when combined with Bortezomib. Approved Imiquimod The metabolism of Imiquimod can be decreased when combined with Bortezomib. Approved, Investigational Indacaterol The metabolism of Indacaterol can be decreased when combined with Bortezomib. Approved Indapamide The metabolism of Indapamide can be decreased when combined with Bortezomib. Approved Indinavir The serum concentration of Bortezomib can be increased when it is combined with Indinavir. Approved Indoramin The risk or severity of adverse effects can be increased when Bortezomib is combined with Indoramin. Withdrawn Ipecac The metabolism of Ipecac can be decreased when combined with Bortezomib. Approved, Withdrawn Irbesartan The metabolism of Bortezomib can be decreased when combined with Irbesartan. Approved, Investigational Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Bortezomib. Approved, Investigational Isavuconazole The serum concentration of Bortezomib can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Isavuconazonium can be decreased when combined with Bortezomib. Approved, Investigational Isocarboxazid The risk or severity of adverse effects can be increased when Bortezomib is combined with Isocarboxazid. Approved Isoflurane The risk or severity of adverse effects can be increased when Bortezomib is combined with Isoflurane. Approved, Vet Approved Isoniazid The metabolism of Bortezomib can be decreased when combined with Isoniazid. Approved, Investigational Isosorbide Dinitrate The risk or severity of adverse effects can be increased when Bortezomib is combined with Isosorbide Dinitrate. Approved, Investigational Isosorbide Mononitrate The metabolism of Isosorbide Mononitrate can be decreased when combined with Bortezomib. Approved Isoxsuprine The risk or severity of adverse effects can be increased when Bortezomib is combined with Isoxsuprine. Approved, Withdrawn Isradipine The risk or severity of adverse effects can be increased when Bortezomib is combined with Isradipine. Approved, Investigational Itraconazole The serum concentration of Bortezomib can be increased when it is combined with Itraconazole. Approved, Investigational Ivabradine The serum concentration of Ivabradine can be increased when it is combined with Bortezomib. Approved Ivacaftor The serum concentration of Ivacaftor can be increased when it is combined with Bortezomib. Approved Ivermectin The metabolism of Ivermectin can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Ixabepilone The metabolism of Ixabepilone can be decreased when combined with Bortezomib. Approved, Investigational Ixazomib The metabolism of Ixazomib can be decreased when combined with Bortezomib. Approved, Investigational Ketamine The metabolism of Ketamine can be decreased when combined with Bortezomib. Approved, Vet Approved Ketazolam The metabolism of Ketazolam can be decreased when combined with Bortezomib. Approved Ketobemidone The metabolism of Ketobemidone can be decreased when combined with Bortezomib. Approved, Investigational Ketoconazole The serum concentration of Bortezomib can be increased when it is combined with Ketoconazole. Approved, Investigational Labetalol The risk or severity of adverse effects can be increased when Bortezomib is combined with Labetalol. Approved Lacidipine Bortezomib may increase the hypotensive activities of Lacidipine. Approved, Investigational Lanatoside C Lanatoside C may decrease the cardiotoxic activities of Bortezomib. Experimental Lansoprazole The metabolism of Lansoprazole can be decreased when combined with Bortezomib. Approved, Investigational Lapatinib The metabolism of Lapatinib can be decreased when combined with Bortezomib. Approved, Investigational Laquinimod The metabolism of Laquinimod can be decreased when combined with Bortezomib. Investigational Leflunomide The metabolism of Leflunomide can be decreased when combined with Bortezomib. Approved, Investigational Lenvatinib The metabolism of Lenvatinib can be decreased when combined with Bortezomib. Approved, Investigational Lercanidipine The risk or severity of adverse effects can be increased when Bortezomib is combined with Lercanidipine. Approved, Investigational Letrozole The metabolism of Letrozole can be decreased when combined with Bortezomib. Approved, Investigational Leuprolide Bortezomib may increase the QTc-prolonging activities of Leuprolide. Approved, Investigational Levobunolol The risk or severity of adverse effects can be increased when Bortezomib is combined with Levobunolol. Approved Levobupivacaine The metabolism of Levobupivacaine can be decreased when combined with Bortezomib. Approved, Investigational Levocetirizine The metabolism of Levocetirizine can be decreased when combined with Bortezomib. Approved Levodopa Bortezomib may increase the orthostatic hypotensive activities of Levodopa. Approved Levofloxacin Bortezomib may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Levomethadyl Acetate The metabolism of Levomethadyl Acetate can be decreased when combined with Bortezomib. Approved, Investigational Levomilnacipran The metabolism of Levomilnacipran can be decreased when combined with Bortezomib. Approved, Investigational Levosimendan The risk or severity of adverse effects can be increased when Bortezomib is combined with Levosimendan. Approved, Investigational Levothyroxine The metabolism of Levothyroxine can be decreased when combined with Bortezomib. Approved Lidocaine The metabolism of Lidocaine can be decreased when combined with Bortezomib. Approved, Vet Approved Lipegfilgrastim Bortezomib may increase the myelosuppressive activities of Lipegfilgrastim. Approved, Investigational Lisinopril The risk or severity of adverse effects can be increased when Bortezomib is combined with Lisinopril. Approved, Investigational Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Bortezomib. Approved, Investigational Lobeglitazone The metabolism of Bortezomib can be decreased when combined with Lobeglitazone. Approved, Investigational Lofexidine The risk or severity of adverse effects can be increased when Bortezomib is combined with Lofexidine. Approved, Investigational Lomefloxacin The metabolism of Lomefloxacin can be decreased when combined with Bortezomib. Approved, Investigational Lomitapide The serum concentration of Lomitapide can be increased when it is combined with Bortezomib. Approved, Investigational Lopinavir The serum concentration of Bortezomib can be increased when it is combined with Lopinavir. Approved Loratadine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Loratadine. Approved, Investigational Lorcaserin The metabolism of Lorcaserin can be decreased when combined with Bortezomib. Approved Lorpiprazole The serum concentration of Bortezomib can be increased when it is combined with Lorpiprazole. Approved Losartan The risk or severity of adverse effects can be increased when Bortezomib is combined with Losartan. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Bortezomib. Approved, Investigational Luliconazole The serum concentration of Bortezomib can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Bortezomib can be decreased when it is combined with Lumacaftor. Approved Lumefantrine Bortezomib may increase the QTc-prolonging activities of Lumefantrine. Approved Lumiracoxib The metabolism of Lumiracoxib can be decreased when combined with Bortezomib. Approved, Investigational Lurasidone The serum concentration of Lurasidone can be increased when it is combined with Bortezomib. Approved, Investigational Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Bortezomib. Illicit, Investigational, Withdrawn Macimorelin The metabolism of Macimorelin can be decreased when combined with Bortezomib. Approved, Investigational Macitentan The metabolism of Macitentan can be decreased when combined with Bortezomib. Approved Malathion The metabolism of Malathion can be decreased when combined with Bortezomib. Approved, Investigational Mannitol The risk or severity of adverse effects can be increased when Bortezomib is combined with Mannitol. Approved, Investigational Maprotiline The metabolism of Maprotiline can be decreased when combined with Bortezomib. Approved, Investigational Maraviroc The metabolism of Maraviroc can be decreased when combined with Bortezomib. Approved, Investigational Mebendazole The metabolism of Mebendazole can be decreased when combined with Bortezomib. Approved, Vet Approved Mecamylamine The risk or severity of adverse effects can be increased when Bortezomib is combined with Mecamylamine. Approved, Investigational Medical Cannabis The metabolism of Medical Cannabis can be decreased when combined with Bortezomib. Experimental, Investigational Medroxyprogesterone acetate The metabolism of Medroxyprogesterone acetate can be decreased when combined with Bortezomib. Approved, Investigational Mefloquine The metabolism of Mefloquine can be decreased when combined with Bortezomib. Approved, Investigational Melatonin The metabolism of Melatonin can be decreased when combined with Bortezomib. Approved, Nutraceutical, Vet Approved Meloxicam The metabolism of Meloxicam can be decreased when combined with Bortezomib. Approved, Vet Approved Menadione The metabolism of Menadione can be decreased when combined with Bortezomib. Approved, Nutraceutical Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Bortezomib. Investigational, Withdrawn Mepyramine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Mepyramine. Approved, Vet Approved Metamizole The risk or severity of myelosuppression can be increased when Metamizole is combined with Bortezomib. Approved, Investigational, Withdrawn Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Bortezomib. Experimental Methadone The metabolism of Methadone can be decreased when combined with Bortezomib. Approved Methaqualone The metabolism of Methaqualone can be decreased when combined with Bortezomib. Illicit, Withdrawn Methazolamide The risk or severity of adverse effects can be increased when Bortezomib is combined with Methazolamide. Approved Methimazole The risk or severity of adverse effects can be increased when Bortezomib is combined with Methimazole. Approved Methohexital Methohexital may increase the hypotensive activities of Bortezomib. Approved Methotrimeprazine The metabolism of Bortezomib can be decreased when combined with Methotrimeprazine. Approved, Investigational Methoxyflurane The metabolism of Methoxyflurane can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Methsuximide The metabolism of Methsuximide can be decreased when combined with Bortezomib. Approved Methyclothiazide The risk or severity of adverse effects can be increased when Bortezomib is combined with Methyclothiazide. Approved Methyldopa The risk or severity of adverse effects can be increased when Bortezomib is combined with Methyldopa. Approved Methylergometrine The risk or severity of adverse effects can be increased when Methylergometrine is combined with Bortezomib. Approved Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Bortezomib. Approved, Vet Approved Methyltestosterone The metabolism of Methyltestosterone can be decreased when combined with Bortezomib. Approved Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Bortezomib. Approved Metildigoxin Metildigoxin may decrease the cardiotoxic activities of Bortezomib. Experimental Metipranolol The risk or severity of adverse effects can be increased when Bortezomib is combined with Metipranolol. Approved Metoclopramide The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Metoclopramide. Approved, Investigational Metolazone The risk or severity of adverse effects can be increased when Bortezomib is combined with Metolazone. Approved Metoprolol The risk or severity of adverse effects can be increased when Bortezomib is combined with Metoprolol. Approved, Investigational Metronidazole The metabolism of Metronidazole can be decreased when combined with Bortezomib. Approved Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Bortezomib. Experimental Mexiletine The metabolism of Bortezomib can be decreased when combined with Mexiletine. Approved, Investigational Mianserin The metabolism of Mianserin can be decreased when combined with Bortezomib. Approved, Investigational Mibefradil The serum concentration of Bortezomib can be increased when it is combined with Mibefradil. Investigational, Withdrawn Miconazole The metabolism of Bortezomib can be decreased when combined with Miconazole. Approved, Investigational, Vet Approved Midazolam The metabolism of Midazolam can be decreased when combined with Bortezomib. Approved, Illicit Midecamycin The metabolism of Midecamycin can be decreased when combined with Bortezomib. Approved Midostaurin The metabolism of Bortezomib can be decreased when combined with Midostaurin. Approved, Investigational Mifepristone The serum concentration of Bortezomib can be increased when it is combined with Mifepristone. Approved, Investigational Minoxidil The risk or severity of adverse effects can be increased when Bortezomib is combined with Minoxidil. Approved, Investigational Mirabegron The metabolism of Mirabegron can be decreased when combined with Bortezomib. Approved Mirtazapine The metabolism of Mirtazapine can be decreased when combined with Bortezomib. Approved Mitotane The serum concentration of Bortezomib can be decreased when it is combined with Mitotane. Approved Modafinil The metabolism of Modafinil can be decreased when combined with Bortezomib. Approved, Investigational Moexipril The risk or severity of adverse effects can be increased when Bortezomib is combined with Moexipril. Approved Montelukast The metabolism of Montelukast can be decreased when combined with Bortezomib. Approved Morphine The metabolism of Morphine can be decreased when combined with Bortezomib. Approved, Investigational Moxifloxacin The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Moxifloxacin. Approved, Investigational Moxonidine The risk or severity of adverse effects can be increased when Bortezomib is combined with Moxonidine. Approved, Investigational Muraglitazar The metabolism of Muraglitazar can be decreased when combined with Bortezomib. Investigational Mycophenolate mofetil The metabolism of Mycophenolate mofetil can be decreased when combined with Bortezomib. Approved, Investigational Nabilone The risk or severity of adverse effects can be increased when Bortezomib is combined with Nabilone. Approved, Investigational Nabiximols The metabolism of Nabiximols can be decreased when combined with Bortezomib. Approved, Investigational Nabumetone The metabolism of Nabumetone can be decreased when combined with Bortezomib. Approved Nadolol The risk or severity of adverse effects can be increased when Bortezomib is combined with Nadolol. Approved Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Bortezomib. Approved Naloxone The metabolism of Naloxone can be decreased when combined with Bortezomib. Approved, Vet Approved Naproxen The metabolism of Naproxen can be decreased when combined with Bortezomib. Approved, Vet Approved Nateglinide The metabolism of Nateglinide can be decreased when combined with Bortezomib. Approved, Investigational Nebivolol The risk or severity of adverse effects can be increased when Bortezomib is combined with Nebivolol. Approved, Investigational Nefazodone The serum concentration of Bortezomib can be increased when it is combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of Bortezomib can be increased when it is combined with Nelfinavir. Approved Neratinib The metabolism of Neratinib can be decreased when combined with Bortezomib. Approved, Investigational Nesiritide The risk or severity of adverse effects can be increased when Bortezomib is combined with Nesiritide. Approved, Investigational Netupitant The serum concentration of Bortezomib can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The serum concentration of Bortezomib can be decreased when it is combined with Nevirapine. Approved Nicardipine The risk or severity of adverse effects can be increased when Bortezomib is combined with Nicardipine. Approved, Investigational Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Bortezomib. Approved, Investigational Nicorandil Nicorandil may increase the hypotensive activities of Bortezomib. Approved, Investigational Nicotine The metabolism of Nicotine can be decreased when combined with Bortezomib. Approved Nifedipine The risk or severity of adverse effects can be increased when Bortezomib is combined with Nifedipine. Approved Nilotinib Bortezomib may increase the QTc-prolonging activities of Nilotinib. Approved, Investigational Nilvadipine The risk or severity of adverse effects can be increased when Bortezomib is combined with Nilvadipine. Approved, Investigational Nimodipine The serum concentration of Nimodipine can be increased when it is combined with Bortezomib. Approved, Investigational Nisoldipine The risk or severity of adverse effects can be increased when Bortezomib is combined with Nisoldipine. Approved Nitrazepam The metabolism of Nitrazepam can be decreased when combined with Bortezomib. Approved Nitrendipine The risk or severity of adverse effects can be increased when Bortezomib is combined with Nitrendipine. Approved, Investigational Nitric Oxide The metabolism of Nitric Oxide can be decreased when combined with Bortezomib. Approved Nitroglycerin The risk or severity of adverse effects can be increased when Bortezomib is combined with Nitroglycerin. Approved, Investigational Nitroprusside The risk or severity of adverse effects can be increased when Bortezomib is combined with Nitroprusside. Approved, Investigational Nitrous acid The risk or severity of adverse effects can be increased when Bortezomib is combined with Nitrous acid. Approved, Investigational Norethisterone The metabolism of Norethisterone can be decreased when combined with Bortezomib. Approved Norgestrel The metabolism of Norgestrel can be decreased when combined with Bortezomib. Approved Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Bortezomib. Approved Obinutuzumab The risk or severity of adverse effects can be increased when Bortezomib is combined with Obinutuzumab. Approved, Investigational Odanacatib The metabolism of Odanacatib can be decreased when combined with Bortezomib. Investigational Ofloxacin Bortezomib may increase the QTc-prolonging activities of Ofloxacin. Approved Olanzapine The metabolism of Olanzapine can be decreased when combined with Bortezomib. Approved, Investigational Olaparib The serum concentration of Olaparib can be increased when it is combined with Bortezomib. Approved Oleandrin Oleandrin may decrease the cardiotoxic activities of Bortezomib. Experimental, Investigational Olmesartan The risk or severity of adverse effects can be increased when Bortezomib is combined with Olmesartan. Approved, Investigational Olopatadine The metabolism of Olopatadine can be decreased when combined with Bortezomib. Approved Omeprazole The metabolism of Omeprazole can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Ondansetron The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ondansetron. Approved Opium The metabolism of Opium can be decreased when combined with Bortezomib. Approved, Illicit Orphenadrine The metabolism of Orphenadrine can be decreased when combined with Bortezomib. Approved Osimertinib The serum concentration of Bortezomib can be increased when it is combined with Osimertinib. Approved Ospemifene The metabolism of Ospemifene can be decreased when combined with Bortezomib. Approved, Investigational Ouabain Ouabain may decrease the cardiotoxic activities of Bortezomib. Approved Oxaliplatin The metabolism of Oxaliplatin can be decreased when combined with Bortezomib. Approved, Investigational Oxazepam The metabolism of Oxazepam can be decreased when combined with Bortezomib. Approved Oxprenolol The risk or severity of adverse effects can be increased when Bortezomib is combined with Oxprenolol. Approved Oxtriphylline The metabolism of Oxtriphylline can be decreased when combined with Bortezomib. Approved Oxybutynin The metabolism of Oxybutynin can be decreased when combined with Bortezomib. Approved, Investigational Palbociclib The serum concentration of Bortezomib can be increased when it is combined with Palbociclib. Approved, Investigational Paliperidone Bortezomib may increase the QTc-prolonging activities of Paliperidone. Approved Palonosetron The metabolism of Palonosetron can be decreased when combined with Bortezomib. Approved, Investigational Panobinostat The serum concentration of Bortezomib can be increased when it is combined with Panobinostat. Approved, Investigational Pantoprazole The metabolism of Pantoprazole can be decreased when combined with Bortezomib. Approved Papaverine The risk or severity of adverse effects can be increased when Bortezomib is combined with Papaverine. Approved, Investigational Paramethadione The metabolism of Paramethadione can be decreased when combined with Bortezomib. Approved Paramethasone The metabolism of Paramethasone can be decreased when combined with Bortezomib. Approved Parecoxib The metabolism of Parecoxib can be decreased when combined with Bortezomib. Approved Paricalcitol The metabolism of Paricalcitol can be decreased when combined with Bortezomib. Approved, Investigational Paritaprevir The metabolism of Paritaprevir can be decreased when combined with Bortezomib. Approved, Investigational Paroxetine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Paroxetine. Approved, Investigational Pazopanib The metabolism of Pazopanib can be decreased when combined with Bortezomib. Approved Peginterferon alfa-2b The serum concentration of Bortezomib can be decreased when it is combined with Peginterferon alfa-2b. Approved Penbutolol The risk or severity of adverse effects can be increased when Bortezomib is combined with Penbutolol. Approved, Investigational Pentamidine The metabolism of Pentamidine can be decreased when combined with Bortezomib. Approved, Investigational Pentobarbital The serum concentration of Bortezomib can be decreased when it is combined with Pentobarbital. Approved, Investigational, Vet Approved Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Bortezomib. Approved, Investigational Perampanel The metabolism of Perampanel can be decreased when combined with Bortezomib. Approved Perflutren Bortezomib may increase the QTc-prolonging activities of Perflutren. Approved Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Bortezomib. Approved, Investigational, Vet Approved, Withdrawn Perindopril The risk or severity of adverse effects can be increased when Bortezomib is combined with Perindopril. Approved Permethrin The metabolism of Permethrin can be decreased when combined with Bortezomib. Approved, Investigational Perospirone The metabolism of Perospirone can be decreased when combined with Bortezomib. Approved Perphenazine The metabolism of Perphenazine can be decreased when combined with Bortezomib. Approved Peruvoside Peruvoside may decrease the cardiotoxic activities of Bortezomib. Experimental Pethidine The metabolism of Pethidine can be decreased when combined with Bortezomib. Approved Phenacetin The metabolism of Phenacetin can be decreased when combined with Bortezomib. Withdrawn Phenelzine The risk or severity of adverse effects can be increased when Bortezomib is combined with Phenelzine. Approved Pheniramine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Pheniramine. Approved Phenobarbital The serum concentration of Bortezomib can be decreased when it is combined with Phenobarbital. Approved, Investigational Phenoxybenzamine The metabolism of Phenoxybenzamine can be decreased when combined with Bortezomib. Approved Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Bortezomib. Approved, Investigational Phentolamine The risk or severity of adverse effects can be increased when Bortezomib is combined with Phentolamine. Approved Phenytoin The serum concentration of Bortezomib can be decreased when it is combined with Phenytoin. Approved, Vet Approved Pilocarpine The metabolism of Pilocarpine can be decreased when combined with Bortezomib. Approved, Investigational Pimecrolimus The metabolism of Pimecrolimus can be decreased when combined with Bortezomib. Approved, Investigational Pimozide The serum concentration of Pimozide can be increased when it is combined with Bortezomib. Approved Pinacidil The metabolism of Pinacidil can be decreased when combined with Bortezomib. Approved Pindolol The risk or severity of adverse effects can be increased when Bortezomib is combined with Pindolol. Approved, Investigational Pioglitazone The metabolism of Pioglitazone can be decreased when combined with Bortezomib. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Bortezomib is combined with Pipamperone. Approved, Investigational Piperaquine The metabolism of Piperaquine can be decreased when combined with Bortezomib. Approved, Investigational Pipotiazine The metabolism of Pipotiazine can be decreased when combined with Bortezomib. Approved, Investigational Pirfenidone The serum concentration of Pirfenidone can be increased when it is combined with Bortezomib. Approved, Investigational Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Bortezomib. Approved Pitolisant The serum concentration of Pitolisant can be increased when it is combined with Bortezomib. Approved, Investigational Podofilox The metabolism of Podofilox can be decreased when combined with Bortezomib. Approved Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Bortezomib. Approved Ponatinib The metabolism of Ponatinib can be decreased when combined with Bortezomib. Approved, Investigational Posaconazole The serum concentration of Bortezomib can be increased when it is combined with Posaconazole. Approved, Investigational, Vet Approved Pramipexole The risk or severity of adverse effects can be increased when Bortezomib is combined with Pramipexole. Approved, Investigational Prasterone The metabolism of Prasterone can be decreased when combined with Bortezomib. Approved, Investigational, Nutraceutical Prasugrel The metabolism of Prasugrel can be decreased when combined with Bortezomib. Approved Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Bortezomib. Approved Prazepam The metabolism of Prazepam can be decreased when combined with Bortezomib. Approved, Illicit Praziquantel The metabolism of Praziquantel can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Prazosin The risk or severity of adverse effects can be increased when Bortezomib is combined with Prazosin. Approved Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Bortezomib. Approved, Vet Approved Prednisone The metabolism of Prednisone can be decreased when combined with Bortezomib. Approved, Vet Approved Primaquine The metabolism of Primaquine can be decreased when combined with Bortezomib. Approved Primidone The serum concentration of Bortezomib can be decreased when it is combined with Primidone. Approved, Vet Approved Procainamide Bortezomib may increase the QTc-prolonging activities of Procainamide. Approved Progesterone The metabolism of Progesterone can be decreased when combined with Bortezomib. Approved, Vet Approved Proguanil The metabolism of Proguanil can be decreased when combined with Bortezomib. Approved Promazine The metabolism of Promazine can be decreased when combined with Bortezomib. Approved, Vet Approved Promethazine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Promethazine. Approved, Investigational Propafenone The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Propafenone. Approved Propiverine The metabolism of Propiverine can be decreased when combined with Bortezomib. Approved, Investigational Propofol The metabolism of Propofol can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Propranolol The risk or severity of adverse effects can be increased when Bortezomib is combined with Propranolol. Approved, Investigational Proscillaridin Proscillaridin may decrease the cardiotoxic activities of Bortezomib. Experimental Pyrazinamide The metabolism of Pyrazinamide can be decreased when combined with Bortezomib. Approved, Investigational Pyrimethamine The metabolism of Bortezomib can be decreased when combined with Pyrimethamine. Approved, Investigational, Vet Approved Quazepam The metabolism of Quazepam can be decreased when combined with Bortezomib. Approved, Illicit Quetiapine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Quetiapine. Approved Quinacrine The metabolism of Quinacrine can be decreased when combined with Bortezomib. Approved, Investigational Quinapril The risk or severity of adverse effects can be increased when Bortezomib is combined with Quinapril. Approved, Investigational Quinidine The metabolism of Bortezomib can be decreased when combined with Quinidine. Approved, Investigational Quinine Bortezomib may increase the QTc-prolonging activities of Quinine. Approved Rabeprazole The metabolism of Rabeprazole can be decreased when combined with Bortezomib. Approved, Investigational Raloxifene The metabolism of Raloxifene can be decreased when combined with Bortezomib. Approved, Investigational Ramelteon The metabolism of Ramelteon can be decreased when combined with Bortezomib. Approved, Investigational Ramipril The risk or severity of adverse effects can be increased when Bortezomib is combined with Ramipril. Approved Ranitidine The metabolism of Ranitidine can be decreased when combined with Bortezomib. Approved Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Bortezomib. Approved, Investigational Rasagiline The metabolism of Rasagiline can be decreased when combined with Bortezomib. Approved Reboxetine The metabolism of Reboxetine can be decreased when combined with Bortezomib. Approved, Investigational Regorafenib The metabolism of Regorafenib can be decreased when combined with Bortezomib. Approved Remifentanil The risk or severity of adverse effects can be increased when Bortezomib is combined with Remifentanil. Approved Repaglinide The metabolism of Repaglinide can be decreased when combined with Bortezomib. Approved, Investigational Reserpine The risk or severity of adverse effects can be increased when Bortezomib is combined with Reserpine. Approved, Investigational Resveratrol The metabolism of Resveratrol can be decreased when combined with Bortezomib. Approved, Experimental, Investigational Retapamulin The metabolism of Retapamulin can be decreased when combined with Bortezomib. Approved Rifabutin The serum concentration of Bortezomib can be decreased when it is combined with Rifabutin. Approved, Investigational Rifampicin The serum concentration of Bortezomib can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of Bortezomib can be decreased when it is combined with Rifapentine. Approved, Investigational Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Bortezomib. Approved Riluzole The metabolism of Riluzole can be decreased when combined with Bortezomib. Approved, Investigational Rimonabant The metabolism of Rimonabant can be decreased when combined with Bortezomib. Approved, Investigational Riociguat The metabolism of Riociguat can be decreased when combined with Bortezomib. Approved Risperidone Bortezomib may increase the hypotensive activities of Risperidone. Approved, Investigational Ritonavir The metabolism of Bortezomib can be decreased when combined with Ritonavir. Approved, Investigational Rivaroxaban The metabolism of Rivaroxaban can be decreased when combined with Bortezomib. Approved Rofecoxib The metabolism of Rofecoxib can be decreased when combined with Bortezomib. Approved, Investigational, Withdrawn Rolapitant The metabolism of Rolapitant can be decreased when combined with Bortezomib. Approved, Investigational Romidepsin The metabolism of Romidepsin can be decreased when combined with Bortezomib. Approved, Investigational Ropinirole The risk or severity of adverse effects can be increased when Bortezomib is combined with Ropinirole. Approved, Investigational Ropivacaine The metabolism of Ropivacaine can be decreased when combined with Bortezomib. Approved Rotigotine The metabolism of Rotigotine can be decreased when combined with Bortezomib. Approved Roxithromycin The metabolism of Roxithromycin can be decreased when combined with Bortezomib. Approved, Investigational, Withdrawn Rucaparib The metabolism of Rucaparib can be decreased when combined with Bortezomib. Approved, Investigational Rupatadine The metabolism of Rupatadine can be decreased when combined with Bortezomib. Approved Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Bortezomib. Approved Sacubitril The risk or severity of adverse effects can be increased when Bortezomib is combined with Sacubitril. Approved Safinamide The metabolism of Safinamide can be decreased when combined with Bortezomib. Approved, Investigational Salbutamol The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Salbutamol. Approved, Vet Approved Salmeterol The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Salmeterol. Approved Saquinavir The serum concentration of Bortezomib can be increased when it is combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Bortezomib can be decreased when used in combination with Sarilumab. Approved, Investigational Secobarbital The metabolism of Bortezomib can be increased when combined with Secobarbital. Approved, Vet Approved Selegiline The metabolism of Selegiline can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Selexipag The metabolism of Selexipag can be decreased when combined with Bortezomib. Approved Seratrodast The metabolism of Seratrodast can be decreased when combined with Bortezomib. Approved Sertindole The metabolism of Sertindole can be decreased when combined with Bortezomib. Approved, Investigational, Withdrawn Sertraline The metabolism of Sertraline can be decreased when combined with Bortezomib. Approved Sevoflurane The metabolism of Sevoflurane can be decreased when combined with Bortezomib. Approved, Vet Approved Sibutramine The metabolism of Sibutramine can be decreased when combined with Bortezomib. Approved, Illicit, Investigational, Withdrawn Sildenafil The metabolism of Sildenafil can be decreased when combined with Bortezomib. Approved, Investigational Silodosin The metabolism of Silodosin can be decreased when combined with Bortezomib. Approved Siltuximab The serum concentration of Bortezomib can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Bortezomib can be increased when it is combined with Simeprevir. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Bortezomib. Approved Sirolimus The metabolism of Sirolimus can be decreased when combined with Bortezomib. Approved, Investigational Solifenacin The metabolism of Solifenacin can be decreased when combined with Bortezomib. Approved Sonidegib The serum concentration of Sonidegib can be increased when it is combined with Bortezomib. Approved, Investigational Sorafenib The metabolism of Sorafenib can be decreased when combined with Bortezomib. Approved, Investigational Sotalol Bortezomib may increase the QTc-prolonging activities of Sotalol. Approved Spiramycin The metabolism of Spiramycin can be decreased when combined with Bortezomib. Approved Spironolactone The risk or severity of adverse effects can be increased when Bortezomib is combined with Spironolactone. Approved St. John's Wort The serum concentration of Bortezomib can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Bortezomib can be increased when it is combined with Stiripentol. Approved Streptokinase The risk or severity of adverse effects can be increased when Bortezomib is combined with Streptokinase. Approved, Investigational Sufentanil The metabolism of Sufentanil can be decreased when combined with Bortezomib. Approved, Investigational Sulfadiazine The metabolism of Bortezomib can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Sulfamethoxazole The metabolism of Sulfamethoxazole can be decreased when combined with Bortezomib. Approved Sulfasalazine The risk or severity of adverse effects can be increased when Bortezomib is combined with Sulfasalazine. Approved Sulfinpyrazone The metabolism of Sulfinpyrazone can be decreased when combined with Bortezomib. Approved Sulfisoxazole The metabolism of Bortezomib can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sunitinib The metabolism of Sunitinib can be decreased when combined with Bortezomib. Approved, Investigational Suvorexant The serum concentration of Suvorexant can be increased when it is combined with Bortezomib. Approved, Investigational Synthetic Conjugated Estrogens, A The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Bortezomib. Approved Synthetic Conjugated Estrogens, B The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Bortezomib. Approved Tacrine The metabolism of Tacrine can be decreased when combined with Bortezomib. Investigational, Withdrawn Tacrolimus The metabolism of Tacrolimus can be decreased when combined with Bortezomib. Approved, Investigational Tadalafil The metabolism of Tadalafil can be decreased when combined with Bortezomib. Approved, Investigational Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Bortezomib. Approved Tamsulosin The metabolism of Tamsulosin can be decreased when combined with Bortezomib. Approved, Investigational Tasosartan The metabolism of Tasosartan can be decreased when combined with Bortezomib. Approved Taurochenodeoxycholic acid The metabolism of Taurochenodeoxycholic acid can be decreased when combined with Bortezomib. Experimental Telaprevir The serum concentration of Bortezomib can be increased when it is combined with Telaprevir. Approved, Withdrawn Telavancin Bortezomib may increase the QTc-prolonging activities of Telavancin. Approved Telithromycin The serum concentration of Bortezomib can be increased when it is combined with Telithromycin. Approved Telmisartan The risk or severity of adverse effects can be increased when Bortezomib is combined with Telmisartan. Approved, Investigational Temafloxacin The metabolism of Temafloxacin can be decreased when combined with Bortezomib. Withdrawn Temazepam The metabolism of Temazepam can be decreased when combined with Bortezomib. Approved, Investigational Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Bortezomib. Approved Teniposide The metabolism of Teniposide can be decreased when combined with Bortezomib. Approved Tenofovir disoproxil The metabolism of Bortezomib can be decreased when combined with Tenofovir disoproxil. Approved, Investigational Terazosin The risk or severity of adverse effects can be increased when Bortezomib is combined with Terazosin. Approved Terbinafine The metabolism of Terbinafine can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Terfenadine The metabolism of Terfenadine can be decreased when combined with Bortezomib. Approved, Withdrawn Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Bortezomib. Experimental Teriflunomide The serum concentration of Bortezomib can be decreased when it is combined with Teriflunomide. Approved Terodiline The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Terodiline. Experimental Tesmilifene The metabolism of Tesmilifene can be decreased when combined with Bortezomib. Investigational Testosterone The metabolism of Testosterone can be decreased when combined with Bortezomib. Approved, Investigational Testosterone cypionate The metabolism of Testosterone cypionate can be decreased when combined with Bortezomib. Approved Testosterone enanthate The metabolism of Testosterone enanthate can be decreased when combined with Bortezomib. Approved Testosterone propionate The metabolism of Testosterone propionate can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved, Withdrawn Testosterone undecanoate The metabolism of Testosterone undecanoate can be decreased when combined with Bortezomib. Approved, Investigational Tetrabenazine Bortezomib may increase the QTc-prolonging activities of Tetrabenazine. Approved, Investigational Tetrandrine The risk or severity of adverse effects can be increased when Bortezomib is combined with Tetrandrine. Experimental Tezacaftor The metabolism of Tezacaftor can be decreased when combined with Bortezomib. Approved, Investigational Thalidomide The metabolism of Thalidomide can be decreased when combined with Bortezomib. Approved, Investigational, Withdrawn Theobromine The metabolism of Theobromine can be decreased when combined with Bortezomib. Approved, Investigational Theophylline The metabolism of Theophylline can be decreased when combined with Bortezomib. Approved Thiabendazole The metabolism of Thiabendazole can be decreased when combined with Bortezomib. Approved, Vet Approved Thiamylal Thiamylal may increase the hypotensive activities of Bortezomib. Approved, Vet Approved Thiopental Thiopental may increase the hypotensive activities of Bortezomib. Approved, Vet Approved Thioridazine The serum concentration of Thioridazine can be increased when it is combined with Bortezomib. Approved, Withdrawn Thiotepa The metabolism of Thiotepa can be decreased when combined with Bortezomib. Approved, Investigational Thiothixene The metabolism of Thiothixene can be decreased when combined with Bortezomib. Approved Tiagabine The metabolism of Tiagabine can be decreased when combined with Bortezomib. Approved, Investigational Ticagrelor The metabolism of Ticagrelor can be decreased when combined with Bortezomib. Approved Ticlopidine The metabolism of Bortezomib can be decreased when combined with Ticlopidine. Approved Tinidazole The metabolism of Tinidazole can be decreased when combined with Bortezomib. Approved, Investigational Tiotropium The metabolism of Tiotropium can be decreased when combined with Bortezomib. Approved Tipranavir The metabolism of Bortezomib can be decreased when combined with Tipranavir. Approved, Investigational Tizanidine The serum concentration of Tizanidine can be increased when it is combined with Bortezomib. Approved, Investigational Tocilizumab The serum concentration of Bortezomib can be decreased when it is combined with Tocilizumab. Approved Tocofersolan The metabolism of Tocofersolan can be decreased when combined with Bortezomib. Approved Tocopherol The metabolism of Tocopherol can be decreased when combined with Bortezomib. Approved, Investigational Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Bortezomib. Approved, Investigational Tolazoline The risk or severity of adverse effects can be increased when Bortezomib is combined with Tolazoline. Approved, Vet Approved Tolbutamide The metabolism of Bortezomib can be decreased when combined with Tolbutamide. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Bortezomib is combined with Tolcapone. Approved, Withdrawn Tolperisone The metabolism of Tolperisone can be decreased when combined with Bortezomib. Approved, Investigational Tolterodine The metabolism of Tolterodine can be decreased when combined with Bortezomib. Approved, Investigational Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Bortezomib. Approved Topiroxostat The metabolism of Bortezomib can be decreased when combined with Topiroxostat. Approved, Investigational Torasemide The risk or severity of adverse effects can be increased when Bortezomib is combined with Torasemide. Approved Toremifene Bortezomib may increase the QTc-prolonging activities of Toremifene. Approved, Investigational Trabectedin The metabolism of Trabectedin can be decreased when combined with Bortezomib. Approved, Investigational Trandolapril The risk or severity of adverse effects can be increased when Bortezomib is combined with Trandolapril. Approved Tranylcypromine The metabolism of Bortezomib can be decreased when combined with Tranylcypromine. Approved, Investigational Trastuzumab Trastuzumab may increase the cardiotoxic activities of Bortezomib. Approved, Investigational Trastuzumab emtansine The metabolism of Trastuzumab emtansine can be decreased when combined with Bortezomib. Approved, Investigational Trazodone The metabolism of Trazodone can be decreased when combined with Bortezomib. Approved, Investigational Tretinoin The metabolism of Tretinoin can be decreased when combined with Bortezomib. Approved, Investigational, Nutraceutical Triamcinolone The metabolism of Triamcinolone can be decreased when combined with Bortezomib. Approved, Vet Approved Triamterene The metabolism of Triamterene can be decreased when combined with Bortezomib. Approved Triazolam The metabolism of Triazolam can be decreased when combined with Bortezomib. Approved, Investigational Trifluoperazine The metabolism of Trifluoperazine can be decreased when combined with Bortezomib. Approved, Investigational Trimethoprim The metabolism of Trimethoprim can be decreased when combined with Bortezomib. Approved, Vet Approved Trimipramine The metabolism of Trimipramine can be decreased when combined with Bortezomib. Approved Troglitazone The metabolism of Troglitazone can be decreased when combined with Bortezomib. Investigational, Withdrawn Troleandomycin The metabolism of Troleandomycin can be decreased when combined with Bortezomib. Approved Udenafil The metabolism of Udenafil can be decreased when combined with Bortezomib. Approved, Investigational Ulipristal The serum concentration of Ulipristal can be increased when it is combined with Bortezomib. Approved Vadimezan The metabolism of Vadimezan can be decreased when combined with Bortezomib. Investigational Valbenazine The metabolism of Valbenazine can be decreased when combined with Bortezomib. Approved, Investigational Valdecoxib The metabolism of Valdecoxib can be decreased when combined with Bortezomib. Approved, Investigational, Withdrawn Valproic Acid The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Valproic Acid. Approved, Investigational Valsartan The metabolism of Bortezomib can be decreased when combined with Valsartan. Approved, Investigational Vandetanib Bortezomib may increase the QTc-prolonging activities of Vandetanib. Approved Vanoxerine The metabolism of Vanoxerine can be decreased when combined with Bortezomib. Investigational Vardenafil The metabolism of Vardenafil can be decreased when combined with Bortezomib. Approved Velpatasvir The metabolism of Velpatasvir can be decreased when combined with Bortezomib. Approved, Investigational Vemurafenib The serum concentration of Bortezomib can be increased when it is combined with Vemurafenib. Approved Venetoclax The metabolism of Venetoclax can be decreased when combined with Bortezomib. Approved, Investigational Venlafaxine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Venlafaxine. Approved Verapamil The risk or severity of adverse effects can be increased when Bortezomib is combined with Verapamil. Approved Vicriviroc The metabolism of Vicriviroc can be decreased when combined with Bortezomib. Investigational Vilanterol The metabolism of Vilanterol can be decreased when combined with Bortezomib. Approved Vilazodone The serum concentration of Vilazodone can be increased when it is combined with Bortezomib. Approved Vinblastine The metabolism of Vinblastine can be decreased when combined with Bortezomib. Approved Vincristine The metabolism of Vincristine can be decreased when combined with Bortezomib. Approved, Investigational Vindesine The serum concentration of Vindesine can be increased when it is combined with Bortezomib. Approved, Investigational Vinflunine The metabolism of Vinflunine can be decreased when combined with Bortezomib. Approved, Investigational Vinorelbine The metabolism of Vinorelbine can be decreased when combined with Bortezomib. Approved, Investigational Vismodegib The metabolism of Vismodegib can be decreased when combined with Bortezomib. Approved, Investigational Voriconazole The serum concentration of Bortezomib can be increased when it is combined with Voriconazole. Approved, Investigational Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Bortezomib. Approved, Investigational Voxilaprevir The metabolism of Voxilaprevir can be decreased when combined with Bortezomib. Approved, Investigational Warfarin The metabolism of Warfarin can be decreased when combined with Bortezomib. Approved Yohimbine The metabolism of Yohimbine can be decreased when combined with Bortezomib. Approved, Investigational, Vet Approved Zafirlukast The metabolism of Zafirlukast can be decreased when combined with Bortezomib. Approved, Investigational Zalcitabine The metabolism of Zalcitabine can be decreased when combined with Bortezomib. Approved, Investigational Zaleplon The metabolism of Zaleplon can be decreased when combined with Bortezomib. Approved, Illicit, Investigational Zidovudine The risk or severity of adverse effects can be increased when Bortezomib is combined with Zidovudine. Approved Zileuton The metabolism of Zileuton can be decreased when combined with Bortezomib. Approved, Investigational, Withdrawn Ziprasidone Bortezomib may increase the QTc-prolonging activities of Ziprasidone. Approved Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Bortezomib. Approved, Investigational Zolpidem The metabolism of Zolpidem can be decreased when combined with Bortezomib. Approved Zomepirac The metabolism of Zomepirac can be decreased when combined with Bortezomib. Withdrawn Zopiclone The serum concentration of Zopiclone can be increased when it is combined with Bortezomib. Approved Zotepine The metabolism of Zotepine can be decreased when combined with Bortezomib. Approved, Investigational, Withdrawn Zucapsaicin The metabolism of Bortezomib can be decreased when combined with Zucapsaicin. Approved, Investigational Zuclopenthixol The serum concentration of Zuclopenthixol can be increased when it is combined with Bortezomib. Approved, Investigational - Food Interactions
- Citrus fruits - Patients should avoid taking extra vitamin C (ascorbic acid) supplements and vitamin C-containing multi-vitamins during their bortezomib therapy. Ascorbic Acid may diminish the therapeutic effect of Bortezomib.
- Green Tea - Green Tea may diminish the antineoplastic effect of Bortezomib. Avoid concurrent use of green tea extract and other green tea products during treatment with bortezomib.
References
- Synthesis Reference
Raghavendracharyulu Venkata Palle, Rajasekhar Kadaboina, Veerendeer Murki, Amarendhar Manda, Nageshwar Gunda, Ramaseshagiri Rao Pulla, Mallesha Hanmanthu, Narasimha Naidu Mopidevi, Suresh Kumar Ramdoss, "BORTEZOMIB AND PROCESS FOR PRODUCING SAME." U.S. Patent US20100226597, issued September 09, 2010.
US20100226597- General References
- Adams J, Kauffman M: Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004;22(2):304-11. [PubMed:15199612]
- Bonvini P, Zorzi E, Basso G, Rosolen A: Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia. 2007 Apr;21(4):838-42. Epub 2007 Feb 1. [PubMed:17268529]
- Voorhees PM, Dees EC, O'Neil B, Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res. 2003 Dec 15;9(17):6316-25. [PubMed:14695130]
- Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 Jun;129(6):755-62. [PubMed:15953001]
- Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22. [PubMed:10363983]
- Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ: Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods. 2005 May;2(5):357-62. Epub 2005 Apr 21. [PubMed:15846363]
- External Links
- Human Metabolome Database
- HMDB0014334
- KEGG Drug
- D03150
- PubChem Compound
- 387447
- PubChem Substance
- 46508736
- ChemSpider
- 343402
- BindingDB
- 50069989
- ChEBI
- 52717
- ChEMBL
- CHEMBL325041
- Therapeutic Targets Database
- DAP001318
- PharmGKB
- PA10252
- HET
- BO2
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Bortezomib
- ATC Codes
- L01XX32 — Bortezomib
- AHFS Codes
- 10:00.00 — Antineoplastic Agents
- PDB Entries
- 2f16 / 3mg0 / 4fwd / 4qvl / 4qvm / 4qvn / 4qvp / 4qvq / 4qvv / 4qvw … show 13 more
- FDA label
- Download (199 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Millennium pharmaceuticals inc
- Packagers
- Ben Venue Laboratories Inc.
- Janssen-Ortho Inc.
- Millennium Pharmaceuticals
- Dosage forms
Form Route Strength Injection, powder, lyophilized, for solution Intravenous 1 mg/mL Injection, powder, for solution Intravenous; Subcutaneous 3.5 mg Powder, for solution Intravenous; Subcutaneous 2.5 mg Injection, powder, for solution Intravenous 1.0 mg Injection, powder, lyophilized, for solution Intravenous; Subcutaneous 3.5 mg/1 Powder, for solution Intravenous; Subcutaneous 3.5 mg - Prices
Unit description Cost Unit Velcade 3.5 mg vial 1590.0USD vial DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US6083903 No 1994-10-28 2014-10-28 US CA2203936 No 2005-04-12 2015-10-27 Canada US5780454 Yes 1997-11-03 2017-11-03 US US6958319 Yes 2002-07-25 2022-07-25 US US6713446 Yes 2002-07-25 2022-07-25 US US8962572 No 2012-11-03 2032-11-03 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility The solubility of bortezomib, as the monomeric boronic acid, is 3.3 to 3.8 mg/mL in a pH range of 2 to 6.5. Not Available - Predicted Properties
Property Value Source Water Solubility 0.0532 mg/mL ALOGPS logP 0.89 ALOGPS logP 1.53 ChemAxon logS -3.9 ALOGPS pKa (Strongest Acidic) 13.04 ChemAxon pKa (Strongest Basic) -0.7 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 124.44 Å2 ChemAxon Rotatable Bond Count 9 ChemAxon Refractivity 99.37 m3·mol-1 ChemAxon Polarizability 40.48 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption - 0.6935 Blood Brain Barrier - 0.6533 Caco-2 permeable - 0.6576 P-glycoprotein substrate Substrate 0.5909 P-glycoprotein inhibitor I Non-inhibitor 0.785 P-glycoprotein inhibitor II Non-inhibitor 1.0 Renal organic cation transporter Non-inhibitor 0.9445 CYP450 2C9 substrate Non-substrate 0.7145 CYP450 2D6 substrate Substrate 0.8918 CYP450 3A4 substrate Non-substrate 0.5209 CYP450 1A2 substrate Non-inhibitor 0.855 CYP450 2C9 inhibitor Non-inhibitor 0.8267 CYP450 2D6 inhibitor Non-inhibitor 0.9304 CYP450 2C19 inhibitor Non-inhibitor 0.8108 CYP450 3A4 inhibitor Non-inhibitor 0.7308 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9604 Ames test Non AMES toxic 0.7439 Carcinogenicity Non-carcinogens 0.8064 Biodegradation Not ready biodegradable 0.9943 Rat acute toxicity 2.4537 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9936 hERG inhibition (predictor II) Non-inhibitor 0.8593
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-0a4i-0035900000-122163b342b985220f63 MS/MS Spectrum - , positive LC-MS/MS splash10-016r-1397000000-e168634cfe7e1453d742
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as phenylalanine and derivatives. These are compounds containing phenylalanine or a derivative thereof resulting from reaction of phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Phenylalanine and derivatives
- Alternative Parents
- N-acyl-alpha amino acids and derivatives / Alpha amino acid amides / Amphetamines and derivatives / Pyrazinecarboxamides / 2-heteroaryl carboxamides / Fatty amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Boronic acids / Organic metalloid salts show 7 more
- Substituents
- Phenylalanine or derivatives / N-acyl-alpha amino acid or derivatives / Alpha-amino acid amide / Amphetamine or derivatives / Pyrazine carboxylic acid or derivatives / Pyrazinecarboxamide / 2-heteroaryl carboxamide / Monocyclic benzene moiety / Fatty amide / Pyrazine show 23 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- pyrazines, amino acid amide, L-phenylalanine derivative (CHEBI:52717)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Threonine-type endopeptidase activity
- Specific Function
- The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly ...
- Gene Name
- PSMB5
- Uniprot ID
- P28074
- Uniprot Name
- Proteasome subunit beta type-5
- Molecular Weight
- 28480.01 Da
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Threonine-type endopeptidase activity
- Specific Function
- The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly ...
- Gene Name
- PSMB1
- Uniprot ID
- P20618
- Uniprot Name
- Proteasome subunit beta type-1
- Molecular Weight
- 26489.09 Da
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- SubstrateInhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- SubstrateInhibitor
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, Hsieh F, Gan LS, Miwa G: Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos. 2005 Jun;33(6):771-7. doi: 10.1124/dmd.104.002956. Epub 2005 Mar 11. [PubMed:15764713]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- SubstrateInhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:36